Resolution of dryness remains a key unmet need for patients with Sjögren disease (SjD), as highlighted by the Sjögren SIG session “How to treat SjD” on the final day of APLAR 2026. A rheumatology talk in the session noted that recent phase III trials of ianalumab, dazodalibep and telitacicept improved ESSDAI scores, with only some evidence of benefit for dryness itself. Symptomatic care therefore still carries the load. Masafumi Moriyama, DDS, PhD, offered practical insight from the oral health side.
All News
Article
Article
Dr. Cush reviews the news and journal reports from this past week on RheumNow. This week on the podcast: hopeful guidelines for PMR; certainty about good & bad beverages in gout; mixed results in Sjogren's; non-lupus drugs saves lupus lives; and big hips sink ships in psoriatic arthritis.
Article
The NEPTUNUS-1 and NEPTUNUS-2 trials have showed that monthly ianalumab is superior of placebo at improving Sjögren’s disease activity at week 48, even though there was no significant ESSDAI response or in the change in SSSD or ESSPRI symptom scores.
Risk factors for mortality in SjD:
> Male sex
> Older age
> Higher clinical ESSDAI score
Keep a closer eye an older male pts with active SjD!
#ACR26 @RheumNow https://t.co/6RFLnrNM6r
The utility of minor salivary gland Bx in suspected SjD:
> Diagnosis of sero(-) patients include pan-negative for ANA/RF/SSA/SSB
> Discovery of an alternative Dx
> Focus score may risk stratify for NHL
(+) Bx also leads the way for clinical trial enrollment
#ACR26 @RheumNow https://t.co/YI999edc3I
Unstimulated whole saliva (UWS) flow rate pearls:
- UWS ≤ 0.1 mL/min part of ACR/EULAR 2016 SjD criteria
- Normal human UWS median 0.48mL/min
- UWS follows circadian rhythm, less in the early AM, increases by lunchtime!
All you need is urine cup and a scale! #ACR26 @RheumNow https://t.co/l3helNwHaT
Tools for lymphoma risk stratification in SjD:
-Salivary gland enlargement
-LAD
-(+) RF
-Raynaud's
-Monoclonal Gammopathy
-Low C4
-(+) SSA and/or SSB
>2 predictive factors enhances lymphoma risk
Consider assessing these at baseline!
#ACR26 @RheumNow https://t.co/Z2odTVCpF0
Don't get burnt by stereotypical thinking; Sjögren's exists without sicca.. or at least its not always a top symptom #ACR26 @RheumNow https://t.co/vjMgHOFjVM
Janet Pope
Tweet
I used to think #SSc #scleroderma pts w #SjD #Sjogren’s did better as more
Mild ‘#CREST’
Nope 👎
#CSRG study N>1000 pts
showed #SjD had
=#mRSS
But
⬆️#GI #gut issues
⬆️ #ILD ? From +#Ro
⬇️worse #QoL
#0231 #ACR26 @ACRheum @RheumNow https://t.co/A4zxpc24XN
Janet Pope
Tweet
#FcRn fails in #SjD
+ early phase results ‘dry’ up in Phase3 #efgartigimod in #Sjogren’s #disease
Will await late breaking + #inflammatory #myositis with efgartigimod @ACRheum #ACR26
abst#LB24
@RheumNow https://t.co/EnOEXuW6jf
Rheum pipeline for neonatal Fc receptor molecules:
Efgartigimod- Ph3 IIM trial completed, Ph2 in LN, SSc and IgG4 in process or complete, SjD program terminated
Nipocalimab - Ph3 in IIM, SLE, SjD
Rozanolixizumab - Ph2 in fibromyalgia terminated
#ACR26 @RheumNow https://t.co/mCYtWVlKOI
Monitoring ILD in SjD: reassess risk at every visit. High risk with disease duration under 1 year: PFTs every 3-6 months, HRCT at 1 year. Lung biopsy has no role in diagnosis, except for atypical HRCT features or to exclude malignancy. #APLAR26 @RheumNow https://t.co/tFPNi0S8y8
Dr. Cush reviews the news and journal reports from this past week on RheumNow. This week on the podcast: hopeful guidelines for PMR; certainty about good & bad beverages in gout; mixed results in Sjogren's; non-lupus drugs saves lupus lives; and big hips sink ships in psoriatic https://t.co/TPqPKP5MRl
The Efficacy of Ianalumab in Sjögren’s Disease
The NEPTUNUS-1 and NEPTUNUS-2 trials have showed that monthly ianalumab is superior of placebo at improving Sjögren’s disease activity at week 48, even though there was no significant ESSDAI response or in the change in SSSD or https://t.co/YStzIFq5Bx
Two crystals in one joint? Cryptococcus risk doubled with JAK inhibitors? And early damage in Sjögren’s linked to a 12–14-fold increase in lymphoma risk?
Dr. Jack Cush breaks down the findings behind the numbers in this week's RheumNow roundup:
- JAK inhibitors: Cryptococcal https://t.co/4RkznhyoIt
FDA has approved NDA for Evoxac, granting Cosette right to sell oral, liquid Evoxac as an alternative treatment option for managing dry mouth symptoms in Sjögren’s patients. NA until end of 2026. https://t.co/jTySNljXMv https://t.co/PCnfAmIB2W
? value of FamHx in Rheum evals? My bias is that few Dz are heritable - #Ank Spondylitis, #gout, DIP Osteoarthritis! But literature says there's high heritability for SLE, RA, systemic sclerosis, Sjögren's, & autoimmune endocrinopathies. WHAT do you think? https://t.co/WGyQqpY1qX
Steroids are easy to start and hard to stop. Hold the MTX, but not the biologic or JAK. And what’s the latest on avacopan?
This week, Dr. Jack Cush reviews the rheumatology news you don’t want to miss: from new approvals and promising trial results to sobering Sjögren’s data, https://t.co/UC4RdHMaFS
Agenx announced it will discontinue its phase 3 UNITY study -efgartigimod SC in adults with mod-to-severe Sjögren's dz, based on not meeting its primary endpoint (clinESSDAIwk 48) & rec from DSMB. ""Sjögren's Disease is one of the most heterogeneous and complicated diseases in https://t.co/fmuzxvaCGx
Amgen announced topline results from the Phase 3 OASIZ 301 study showing the efficacy of dazodalibep in Sjögren's dz, w/ signif ESSDAI improvements at wek 48. DAZO is a CD40L antagonist fusion protein https://t.co/5QPBdZivxC https://t.co/tJvYo6TrWO
